HLS Therapeutics Inc (FRA:74D)
€ 2.38 0.08 (3.48%) Market Cap: 78.06 Mil Enterprise Value: 126.68 Mil PE Ratio: 0 PB Ratio: 1.08 GF Score: 66/100

HLS Therapeutics Inc. - Special Call Transcript

Jul 20, 2020 / 09:30PM GMT
Operator

Good afternoon, and welcome to the July 20, 2020 Investor Update Conference Call for HLS Therapeutics. On today's call, we have Greg Gubitz, Chief Executive Officer; Gilbert Godin, President and Chief Operating Officer; and Tim Hendrickson, Chief Financial Officer. (Operator Instructions)

Certain matters discussed in today's conference call or answers that may be given to questions could constitute forward-looking statements. Actual results could differ materially from those anticipated. Risk factors that could affect results are detailed in the company's annual information form, which has been filed with SEDAR and can be accessed at www.sedar.com.

During this conference call, HLS may refer to adjusted EBITDA. Adjusted EBITDA does not have any standardized meaning prescribed by IFRS. Adjusted EBITDA is defined in the company's press release and annual filings that are available on SEDAR and the company's website. Please note that all financial information provided is in U.S. dollars, unless otherwise specified.

I

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot